Cefazolin (CFZ) is the first-line treatment for beta-lactamase-producing methicillin-sensitive Staphylococcus aureus (BP-MSSA) infection. This evidence concerns the gene LACTB and Methicillin-Susceptible Staphylococcus Aureus Infection.